Zobrazeno 1 - 10
of 27
pro vyhledávání: '"J. Terrill Huggins"'
Publikováno v:
Respiratory Medicine Case Reports, Vol 43, Iss , Pp 101832- (2023)
Complicated parapneumonic effusions and empyemas are associated with significant morbidity and mortality. When managing a potentially infected pleural space, current guidelines support performing diagnostic thoracentesis prior to consideration of che
Externí odkaz:
https://doaj.org/article/f045c5df5208468994e763a25fca3d27
Publikováno v:
Respiratory Medicine Case Reports, Vol 40, Iss , Pp 101745- (2022)
Point-of-care ultrasound is a bedside tool that is increasingly being used as part of the physical examination to evaluate fluid status. Cardiac ultrasound for assessment of volume status focuses on evaluating left ventricular ejection fraction, pres
Externí odkaz:
https://doaj.org/article/e0edea408a8f41eb9ac8cd57bab748ca
Publikováno v:
J Thorac Dis
Disorders of the pleural space are quite common in the critically ill patient. They are generally associated with the underlying illness. It is sometimes difficult to assess for pleural space disorders in the ICU given the instability of some patient
Publikováno v:
The American Journal of Managed Care. 27:S138-S146
Systemic sclerosis (SSc), also referred to as scleroderma, is a rare autoimmune disease associated with vasculopathy, inflammation, and fibrosis of the skin and/or internal organs. Interstitial lung disease (ILD) is a frequent complication and is the
Publikováno v:
American Journal of Nephrology. 50:204-211
Introduction: Fulfillment of the diagnostic criteria for hepatorenal syndrome type 1 (HRS-1) requires prior failure of 2 days of intravenous volume expansion and/or diuretic withdrawal. However, no parameter of volume status is used to guide the ne
Publikováno v:
ASVIDE. 8:260-260
Publikováno v:
ASVIDE. 8:261-261
Autor:
Boris Polman, J. Terrill Huggins, Danielle Antin-Ozerkis, Peter P. LaCamera, Marlies S. Wijsenbeek, Klaus-Uwe Kirchgaessler, Paolo Spagnolo, Wim A. Wuyts, Martina Vasakova, Mary Beth Scholand
Publikováno v:
Respiratory Medicine
Respiratory Medicine, 150, 120-125. W.B. Saunders
Respiratory Medicine, 150, 120-125. W.B. Saunders
BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is a fatal interstitial lung disease characterized by irreversible loss of lung function and an unpredictable course of disease progression. METHODS: The safety data for patients with IPF who received p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::524a3ad02634ddc05ca7a81005f4823d
https://lirias.kuleuven.be/handle/123456789/635787
https://lirias.kuleuven.be/handle/123456789/635787
Autor:
Hilario Nunes, John L. Stauffer, Charlene D. Fell, Marlies S. Wijsenbeek, Ute Petzinger, Robert Sussman, Frank Gilberg, Kevin R. Flaherty, Claudia Valenzuela, J. Terrill Huggins, Monica Bengus
Publikováno v:
European Respiratory Journal, 52(2):1800230. European Respiratory Society
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
We assessed safety and tolerability of treatment with pirfenidone (1602–2403 mg·day −1 ) and nintedanib (200–300 mg·day −1 ) in patients with idiopathic pulmonary fibrosis (IPF). This 24-week, single-arm, open-label, phase IV study (Clinica